Oct 07, 2014 at 12:29 | Source: Moneycontrol.com
Firstcall Research is bullish on Pfizer and has recommended buy rating on the stock with a target of Rs 1797 in its September 29, 2014 research report.
Sep 13, 2014 at 12:41 | Source: Reuters
The lawsuit stems from a 2008 settlement of a patent lawsuit filed by Pfizer against Ranbaxy over Ranbaxy's plan to make generic Lipitor. Under the deal, Pfizer agreed to drop a claim for damages against Ranbaxy, and Ranbaxy agreed to stay out of the Lipitor market until November 2011.
Aug 11, 2014 at 17:40 | Source: CNBC-TV18
Revenue is seen going up by 17.5 percent to Rs 4,115 crore during the quarter from Rs 3,503 crore in the year-ago period driven by US sales.
Aug 08, 2014 at 18:33 | Source: CNBC-TV18
The National Pharmaceutical Pricing Authority on July 10 notified price control on 50 new drugs and the order will reduce the drug prices by 10-35 percent.
Aug 04, 2014 at 08:24 | Source: CNBC-TV18
Tata Motors | TVS Motor | Mahindra and Mahindra | NRB Bearings | TTK Healthcare | Suzlon Energy | Sona Koyo | Bajaj Corp | Panacea Biotec | Godfrey Phillips | 3M India | Bank Of Maharashtra | PTC India Financial | Andhra Bank | Godrej Properties | Pfizer | Tata Power | Persistent and Ipca Labs are stocks, which are in the news today.
Aug 02, 2014 at 11:29 | Source: Moneycontrol.com
Pfizer has issued to all concerned a lock-out notice on August 1, 2014, at its plant situated at Thane Belapur Road, K.U. Bazar P.O., Navi Mumbai 400705.
Aug 01, 2014 at 19:59 | Source: PTI
The Thane manufacturing plant employs 212 workers. This notice for lockout will not impact the supply of any of our products or medicines to patients, Pfizer said.
Jul 31, 2014 at 15:31 | Source: Reuters
On the back of the strong results, AstraZeneca raised its guidance for the full year, predicting sales would hold steady and not decline as previously expected.
Jul 25, 2014 at 21:22 | Source: CNBC-TV18
The pressure is building up on the Indian drug regulator to clampdown on the fake drugs that are inundating the Indian market. A desperate CDSCO has decided to restart an old scheme -- reward to any whistleblower who is instrumental in the seizure of counterfeit drugs and cosmetics.
Jul 25, 2014 at 20:15 | Source: CNBC-TV18
An expert panel consisting Rashesh Shah, Chairman and CEO of the Edelweiss Financial Services Group, Kewal Handa, Former Managing Director of Pfizer India and Piruz Khambatta, Chairman Private limited discuss the agenda for the government beyond Budget 2014s hits and misses on Change Indias second episode.